Clinical trials: Antidepressant
Major Depressive Disorder
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4995819 as adjunctive therapy in patients with major depressive disorder having inadequate…
- Trial name
- NCT01457677
- Testing
- RO4995819
- Where
- 92 sites in United States, Austria and 6 more
- Volunteers
- 357 people
- Sponsor
- Hoffmann-La Roche
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like a medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01197508
- Testing
- TC-5214
- Where
- 87 sites in Argentina, Brazil and 15 more
- Volunteers
- 696 people
- Sponsor
- AstraZeneca
Bipolar Disorder, Bipolar Depression
A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium
This is a study that, in the first 16 weeks, investigates whether lamotrigine versus placebo offers effect on depressive episodes for patients with bipolar disorder (also known as manic depressive disorder) who use lithium.
- Trial name
- NCT00224510
- Testing
- lamotrigine
- Where
- 31 sites in Netherlands, Spain
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal…
- Trial name
- TRANSFORM-1 (NCT02417064)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 90 sites in United States, Belgium and 7 more
- Volunteers
- 346 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
In this study, quetiapine XR or placebo will be administered orally for 6 weeks to major depressive disorder patients with lack of response to existing antidepressants, with the aim of evaluating the efficacy of quetiapine XR and…
- Trial name
- NCT01725282
- Testing
- quetiapine extended release (XR)
- Where
- 3 sites in Japan
- Volunteers
- 172 people
- Sponsor
- Astellas Pharma Inc
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
Open Label Extension for GLYX13-C-202, NCT01684163
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
- Trial name
- NCT02192099
- Testing
- Rapastinel (225 mg/450 mg IV administration)
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depression
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy within 28 days of treatment with approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the…
- Trial name
- NCT02237937
- Testing
- Paroxetine, Sertraline, Citalopram
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HolsboerMaschmeyer NeuroChemie GmbH
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of treating participants with treatment-resistant depression (TRD) who have failed at least 2 (and no more than 6) prior antidepressant (AD) treatments in the current moderate…
- Trial name
- NCT03852160
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Sponsor
- Janssen-Cilag International NV
Depression
Predicting Response to Depression Treatment (PReDicT)
Depression is a very common, serious and in some cases life-threatening condition, affecting around 350 million people globally.
- Trial name
- NCT02790970
- Testing
- PReDicT Test, Treatment as Usual
- Where
- 76 sites in France, Germany and 3 more
- Volunteers
- 913 people
- Sponsor
- P1vital Products Limited
Anxious Major Depressive Disorder
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
This study will determine if a highly selective enkephalinergic receptor modulator is effective in the treatment of anxious major depressive disorder.
- Trial name
- NCT00759395
- Testing
- AZD2327
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Antidepressant Incomplete Response Depression
Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 3 assessment will be carried out .
- Trial name
- DRIA (NCT00782964)
- Where
- 48 sites in Spain
- Volunteers
- 364 people
- Sponsor
- AstraZeneca
Depression
To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions
To demonstrate the relative bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride capsules under fed and fasted conditions.
- Trial name
- NCT00913952
- Testing
- Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions, Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions, Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder
AZD6765 Severe Major Depressive Disorder (MDD) IV
The purpose of this research study is to determine whether AZD6765 has an effect on the patient's depression when taken together with current depression medication.
- Trial name
- NCT00781742
- Testing
- AZD6765
- Where
- 27 sites in United States
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion
The LEAP-DB study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.
- Trial name
- LEAP-DB (NCT04388189)
- Testing
- Duloxetine, Bupropion
- Sponsor
- Alto Neuroscience
Major Depressive Disorder
Switching to Duloxetine From Other Antidepressants
A multicentre, randomised, open label study of out-patients with major depression who have failed to respond adequately to antidepressant treatment for their current episode of depression.
- Trial name
- NCT00191932
- Testing
- Duloxetine
- Where
- 14 sites in France, Ireland and 2 more
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company
Depression
To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions
To demonstrate the relative bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg imipramine hydrochloride tablets in healthy adult volunteers under fasting conditions.
- Trial name
- NCT00946764
- Testing
- Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.), Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sandoz
Depressive Disorder, Major
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram [mg] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an…
- Trial name
- NCT03321526
- Testing
- JNJ-42847922, Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI)
- Where
- 50 sites in United States
- Volunteers
- 107 people
- Sponsor
- Janssen Research & Development, LLC
Depression
To Demonstrate the Relative Bioequivalency of Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets
To demonstrate the relative bioequivalency of comparing single 100 mg doses Of Cord's 50 mg Desipramine Hcl tablets to Merrell Dow's 50 mg Norpramin tablets.
- Trial name
- NCT00914004
- Testing
- Desipramine HCl 50 mg Tablets Cord Laboratories, Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Obesity
Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
The hypothesis of this study is that up to 150 mg of sertraline and up to 3 mg of telenzepine will be safe, tolerable, and have the effect of suppressing appetite, when taken in combination daily by mouth by healthy, overweight…
- Trial name
- NCT01155531
- Testing
- Sertraline plus Telenzepine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theracos